Acrivon Therapeutics (ACRV) Competitors $5.58 +0.22 (+4.10%) Closing price 04:00 PM EasternExtended Trading$5.58 0.00 (0.00%) As of 04:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends ACRV vs. RLAY, TYRA, SANA, DNTH, GHRS, VALN, ABUS, PHAR, LENZ, and CRMDShould you be buying Acrivon Therapeutics stock or one of its competitors? The main competitors of Acrivon Therapeutics include Relay Therapeutics (RLAY), Tyra Biosciences (TYRA), Sana Biotechnology (SANA), Dianthus Therapeutics (DNTH), GH Research (GHRS), Valneva (VALN), Arbutus Biopharma (ABUS), Pharming Group (PHAR), LENZ Therapeutics (LENZ), and CorMedix (CRMD). These companies are all part of the "pharmaceutical products" industry. Acrivon Therapeutics vs. Relay Therapeutics Tyra Biosciences Sana Biotechnology Dianthus Therapeutics GH Research Valneva Arbutus Biopharma Pharming Group LENZ Therapeutics CorMedix Acrivon Therapeutics (NASDAQ:ACRV) and Relay Therapeutics (NASDAQ:RLAY) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, community ranking, institutional ownership, analyst recommendations, risk, profitability and earnings. Does the MarketBeat Community favor ACRV or RLAY? Relay Therapeutics received 26 more outperform votes than Acrivon Therapeutics when rated by MarketBeat users. However, 97.22% of users gave Acrivon Therapeutics an outperform vote while only 70.11% of users gave Relay Therapeutics an outperform vote. CompanyUnderperformOutperformAcrivon TherapeuticsOutperform Votes3597.22% Underperform Votes12.78%Relay TherapeuticsOutperform Votes6170.11% Underperform Votes2629.89% Is ACRV or RLAY more profitable? Relay Therapeutics' return on equity of -45.75% beat Acrivon Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Acrivon TherapeuticsN/A -47.95% -43.73% Relay Therapeutics N/A -45.75%-40.75% Do analysts prefer ACRV or RLAY? Acrivon Therapeutics currently has a consensus price target of $23.67, suggesting a potential upside of 324.13%. Relay Therapeutics has a consensus price target of $19.80, suggesting a potential upside of 484.07%. Given Relay Therapeutics' higher possible upside, analysts clearly believe Relay Therapeutics is more favorable than Acrivon Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Acrivon Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00Relay Therapeutics 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.90 Do institutionals & insiders believe in ACRV or RLAY? 71.6% of Acrivon Therapeutics shares are owned by institutional investors. Comparatively, 97.0% of Relay Therapeutics shares are owned by institutional investors. 8.5% of Acrivon Therapeutics shares are owned by insiders. Comparatively, 4.3% of Relay Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has more volatility & risk, ACRV or RLAY? Acrivon Therapeutics has a beta of 0.77, meaning that its stock price is 23% less volatile than the S&P 500. Comparatively, Relay Therapeutics has a beta of 1.65, meaning that its stock price is 65% more volatile than the S&P 500. Which has higher valuation and earnings, ACRV or RLAY? Acrivon Therapeutics has higher earnings, but lower revenue than Relay Therapeutics. Acrivon Therapeutics is trading at a lower price-to-earnings ratio than Relay Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAcrivon TherapeuticsN/AN/A-$60.39M-$2.70-2.07Relay Therapeutics$10.01M57.43-$341.97M-$2.39-1.42 Does the media prefer ACRV or RLAY? In the previous week, Relay Therapeutics had 15 more articles in the media than Acrivon Therapeutics. MarketBeat recorded 15 mentions for Relay Therapeutics and 0 mentions for Acrivon Therapeutics. Acrivon Therapeutics' average media sentiment score of 1.89 beat Relay Therapeutics' score of 0.15 indicating that Acrivon Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Acrivon Therapeutics Very Positive Relay Therapeutics Neutral SummaryRelay Therapeutics beats Acrivon Therapeutics on 11 of the 16 factors compared between the two stocks. Get Acrivon Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACRV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACRV vs. The Competition Export to ExcelMetricAcrivon TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$173.74M$7.26B$5.85B$8.48BDividend YieldN/A2.78%4.89%3.98%P/E Ratio-2.076.1925.1719.37Price / SalesN/A225.94387.71116.92Price / CashN/A65.6738.0534.62Price / Book1.046.537.364.33Net Income-$60.39M$138.98M$3.18B$246.62M7 Day Performance5.08%-1.64%-2.20%-3.05%1 Month Performance-19.94%-8.91%-6.88%-6.50%1 Year Performance12.96%-11.39%14.29%5.95% Acrivon Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACRVAcrivon Therapeutics1.5687 of 5 stars$5.58+4.1%$23.67+324.1%+6.1%$173.74MN/A-2.0758Positive NewsGap UpRLAYRelay Therapeutics2.2664 of 5 stars$3.88-1.0%$20.50+428.4%-68.6%$649.43M$25.55M-1.49330Earnings ReportNews CoverageTYRATyra Biosciences1.8089 of 5 stars$12.82-2.7%$30.50+137.9%-45.3%$648.69MN/A-7.9620Short Interest ↑News CoverageSANASana Biotechnology2.8733 of 5 stars$2.88-4.3%$14.25+394.8%-72.9%$643.02MN/A-2.06380Upcoming EarningsNews CoverageDNTHDianthus Therapeutics1.7852 of 5 stars$21.60-8.7%$46.83+116.8%-22.0%$639.30M$5.37M-8.6480News CoverageGHRSGH Research2.0191 of 5 stars$12.21-2.4%$30.25+147.7%+15.5%$635.29MN/A-15.4610Earnings ReportUpcoming EarningsShort Interest ↑Positive NewsVALNValneva2.8403 of 5 stars$7.81+5.0%$17.00+117.7%+0.3%$634.64M$165.52M-60.08700Gap UpABUSArbutus Biopharma2.1714 of 5 stars$3.34-2.3%$5.50+64.7%+25.1%$632.90M$6.74M-7.7790Analyst UpgradePHARPharming Group2.6911 of 5 stars$9.17+3.5%$27.00+194.4%-21.4%$623.84M$245.32M-35.27280Short Interest ↓News CoveragePositive NewsGap UpLENZLENZ Therapeutics2.0053 of 5 stars$22.53-4.1%$35.40+57.1%N/A$619.58MN/A0.00110CRMDCorMedix1.5994 of 5 stars$10.10-0.3%$15.67+55.1%+179.0%$612.87M$60,000.00-12.4730Analyst ForecastNews Coverage Related Companies and Tools Related Companies Relay Therapeutics Competitors Tyra Biosciences Competitors Sana Biotechnology Competitors Dianthus Therapeutics Competitors GH Research Competitors Valneva Competitors Arbutus Biopharma Competitors Pharming Group Competitors LENZ Therapeutics Competitors CorMedix Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ACRV) was last updated on 3/5/2025 by MarketBeat.com Staff From Our PartnersElon Musk Wants to Audit Fort Knox—What It Means for Your RetirementYou can take advantage of the coming tariff-fueled gold melt-up right inside your IRA or 401(k) – 100% TAX-FRE...Colonial Metals | Sponsored77 Hedge Funds Are Betting On This Off-Radar MineralWith surging prices... supply shortages... and growing demand, hedge funds are betting big on potash. In fa...The Tomorrow Investor | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredNvidia’s CEO: “This Will Be a Multitrillion-Dollar Industry."If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredWill Trump's Tariffs send this AL stock soaring?If you missed out on Nvidia's massive surge... Don't worry. Because Trump's new tariffs just set the sta...Behind the Markets | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | SponsoredTrump Orders 'National Digital Asset Stockpile'Trump Orders ‘National Digital Asset Stockpile’ THIS could be the coin they choose…Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acrivon Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acrivon Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ACRV Stock Alerts